Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model

European Journal of Pharmacology

Volumn 351, Issue 3, 1998, Pages 341-350

  Feuerstein, Giora ^a   Liu, Gao Lin ^b   Yue, Tian Li ^a   Cheng, H Y ^a   Hieble, J Paul ^a   Arch, Jonathan R S ^a   Ruffolo Jr , Robert R ^a   Ma, X L ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

adrenoceptor antagonist; Carvedilol; Leukocyte; Metoprolol; Myocardial infarction

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PARTITION COEFFICIENT; PRIORITY JOURNAL; REPERFUSION INJURY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CARBAZOLES; HEART RATE; MALE; METOPROLOL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXIDATION-REDUCTION; PEROXIDASE; PROPANOLAMINES; PROPRANOLOL; RABBITS; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECOMBINANT PROTEINS; SOLUBILITY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 0031854958     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00326-4     Document Type: Article

References (23)

1. Australian New Zealand heart failure research collaborative group, 1995. Effect of carvedilol, a vasodilating, β-adrenoceptor antagonist, in patients with congestive heart failure due to ischemic heart disease. Circulation 92, 212-218.
2. Basu, S., Senior, R., Raval, U., Doesrander, R., Bruckner, T., Lahiri, A., 1997. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo controlled, randomized trial. Circulation 96, 183-191.
3. Blin, N., Camoin, L., Maigret, B., Strosberg, A.D., 1993. Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. Mol. Pharmacol. 44, 1094-1104.
4. Bril, A., Slivjak, M., DiMartino, M., Feuerstein, G.Z., Linee, P., Poyser, R.H., Ruffolo Jr., R.R., Smith, E.F., 1992. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: comparison with propranolol. Cardiovasc. Res. 26, 518-525.
5. Bristow, M.R., Gilbert, E.M., Abraham, W.T., Adams, K.F., Fowler, M.B., Hershberger, R.E., Kubo, S.H., Marahara, K.A., Ingersoll, H., Krueger, S., Young, S., Shusterman, N., 1996. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94, 2807-2816.
6. Brunvand, H., Froyland, L., Hexeberg, E., Rynning, S.E., Berge, R.K., Grong, K., 1996a. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur. J. Pharmacol. 314, 99-107.
7. Brunvand, H., Kvitting, P., Rynning, S.E., Berge, R.K., Grong, K., 1996b. Carvedilol protects against lethal reperfusion injury through anti-adrenergic mechanisms. J. Cardiovasc. Pharmacol. 28, 409-417.
8. Dunn, C.J., Spencer, C.M., 1995. Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Drug Aging 7, 394-411.
9. Feuerstein, G.Z., Ruffolo Jr., R.R., 1994. Comparison of the ability of two vasodilating β-adrenoceptor antagonists, carvedilol and celiprolol, to reduce infarct size in a pig model of acute myocardial infarction. Pharmacol. Commun. 5, 57-63.
10. Feuerstein, G.Z., Yue, T.L., Cheng, H.Y., Ruffolo Jr., R.R., 1993. Myocardial protection by the novel vasodilating beta-adrenoceptor antagonist, carvedilol: potential relevance of anti-oxidant activity. J. Hypertens. 1 (Suppl. 4), S41-S48.
11. Feuerstein, G.Z., Poste, G., Ruffolo Jr., R.R., 1995. Carvedilol update III: rationale for use in congestive heart failure. Drug Today 31, 307-326.
12. Feuerstein, G., Shusterman, N., Ruffolo Jr., R.R., 1997. Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drug Today 33, 453-473.
13. Hamburger, S.A., Barone, F.C., Feuerstein, G.Z., Ruffolo Jr., R.R., 1991. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 43, 113-120.
14. 2-adrenoceptor subtypes: therapeutic implications. Expert Opin. Invest. Drugs 6, 367-387.
15. Hjalmarson, A., Elmfeldt, D., Herlitz, J. et al., 1981. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet ii, 823-827.
16. 1L-adrenoceptor in tissue selectivity. Part I. J. Pharmacol. Exp. Ther. 281, 1272-1283.
17. Ma, X.L., Yue, T.L., Lopez, B.L., Barone, F.C., Christopher, T.A., Ruffolo Jr., R.R., Feuerstein, G.Z., 1996. Carvedilol, a new β-adrenoceptor blocker and a free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J. Pharmacol. Exp. Ther. 277, 128-136.
18. Marullo, S., Emorine, L.J., Strosberg, A.D., Delavier-Klutchko, C., 1990. Selective binding of ligands to beta 1, beta 2 or chimeric beta 1/beta 2 adrenergic receptors involves multiple subsites. EMBO J. 9, 1471-1476.
19. Nichols, A.J., Sulpizio, A.C., Ashton, D.J., Hieble, J.P., Ruffolo Jr., R.R., 1989. In vitro pharmacological profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 39, 327-336.
20. Packer, M., Bristow, M.R., Cohn, N.J. et al., 1996. Carvedilol heart failure study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl. J. Med. 334, 1349-1355.
21. Slater, B., McCormack, A., Avdeef, A., Comer, J.E., 1994. pH-Metric log P: 4. Comparison of partition coefficients determined by Shake-Flask HPLC and potentiometric methods. J. Pharm. Sci. 83, 1280-1283.
22. Yue, T.L., McKenna, P.J., Lysko, P.G., Ruffolo Jr., R.R., Feuerstein, G.Z., 1992. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 97, 209-216.
23. Zweier, J.L., Rayburn, B.K., Flaherty, J.T., Weisfeldt, M.L., 1987. Recombinant Superoxide dismutase reduces oxygen free radical concentrations in reperfused myocardium. J. Clin. Invest. 80, 1728-1734.